secwatch.observer — SEC 8-K summary
======================================

Issuer:     Keros Therapeutics, Inc. (KROS)
CIK:        0001664710
Form:       8-K
Filed at:   2026-03-09T23:59:59+00:00
Accession:  0001664710-26-000024
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Keros collaborates with Mass General on Phase 2 ALS trial of rinvatercept; presents new Phase 1 data at MDA Conf.
--------------------------------------------------------------------------------

- Entered agreement with Massachusetts General Hospital for Phase 2 ALS trial within HEALEY ALS MyMatch program.
- Additional Phase 1 data presented at 2026 MDA Conference: rinvatercept generally well-tolerated with no serious adverse events.
- Phase 1 data showed increased muscle mass, decreased fat mass, and increased bone mineral density in healthy volunteers.
- Proteomic analysis confirmed target engagement and anti-fibrotic/anti-inflammatory effects consistent with activin inhibition.
- Keros plans two Phase 2 trials: one in Duchenne muscular dystrophy (DMD) and one in ALS.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1664710/000166471026000024/0001664710-26-000024-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1664710/000166471026000024/kros-20260309.htm
  HTML page:      https://secwatch.observer/filing/0001664710-26-000024

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer